文献速递临床试验与 GCP

比较BARD®LIFESTREAM™覆膜球囊扩张式支架与GORE® VIABAHN™覆膜自膨式支架治疗主髂动脉闭塞性疾病:前瞻性随机对照试验研究方案(NEONATAL试验)

Comparison of BARD®LIFESTREAM™ covered balloon-expandable stent versus GORE® VIABAHN™ covered self-expandable stent in treatment of aortoiliac obstructive disease: study protocol for a prospective randomized controlled trial (NEONATAL trial).
PubMed 文献 · Trials · 2022-05-12

NEONATAL试验是一项前瞻性、单中心、平行、非劣效性随机对照试验,计划纳入106例主髂动脉闭塞性疾病患者,随机分入覆膜球囊扩张式支架组或覆膜自膨式支架组,主要终点为干预后12个月靶病变血运重建的发生率,旨在比较两种覆膜支架的疗效与安全性。

要点

  • 覆膜支架已成为主髂动脉闭塞性疾病主流治疗之一,通畅率高于裸金属支架。
  • 覆膜球囊扩张式支架定位更准确、径向支撑力更高,覆膜自膨式支架弹性与跟踪性更佳。
  • NEONATAL试验为首个比较两种覆膜支架用于主髂动脉闭塞性疾病的随机对照试验。

核心结论

  • NEONATAL试验旨在比较覆膜球囊扩张式支架与覆膜自膨式支架在主髂动脉闭塞性疾病患者中的疗效与安全性,主要比较术后12个月靶病变血运重建率。

研究设计与样本

  • 前瞻性、单中心、平行、非劣效性随机对照试验,计划纳入106例患者,随机分入覆膜球囊扩张式支架组或覆膜自膨式支架组。

主要发现

  • 主要终点为干预后12个月靶病变血运重建的发生率。

关键数值与推荐

  • 主要终点为干预后12个月靶病变血运重建的发生率。
  • 计划纳入106例主髂动脉闭塞性疾病患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Covered stent has become one of the mainstream therapies for aortoiliac obstructive disease (AIOD), with a higher patency rate than bare metal stent. Covered balloon-expandable (CBE) stent can be placed more accurately with higher a radial support force, while covered self-expanding (CSE) stent has greater elasticity and higher trackability. However, there is no level I evidence regarding the comparison safety and efficacy between the CSE stent and CBE stent in AIOD to date. Therefore, this study aims to compare the efficacy and safety of CBE stent (BARD®LIFESTREAM™) and CSE stent (GORE® VIABAHN™) in AIOD. METHODS: This trial is a prospective, single-center, parallel, noninferiority, randomized controlled trial. A total of 106 patients will be enrolled and these patients will be randomized to either the CBE stent group or the CSE stent group. The primary end point of the study is the occurrence of target lesion revascularization (TLR) at 12 months after the intervention. DISCUSSION: To our knowledge, the ballooN sElf cOver steNt AorToiliAc occuLusive (NEONATAL) trial is the first RCT to compare CBE and CSE stent in AIOD patients. The main aim is to compare the TLR of the target lesion between CBE stent and CSE stent at 12 months post-procedure. The results of clinical trials may contribute to establishing a strategic guideline for choosing the optimal type of covered stent in the treatment of AIOD patients. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR2100046734. Registered on 27 May 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Qi Y, Wang J, Zhao J, et al. Comparison of BARD®LIFESTREAM™ covered balloon-expandable stent versus GORE® VIABAHN™ covered self-expandable stent in treatment of aortoiliac obstructive disease: study protocol for a prospective randomized controlled trial (NEONATAL trial). Trials. 2022. PMID: 35549760. doi:10.1186/s13063-022-06332-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。